18F-FDG PET/CT Semiquantitative and Radiomic Features for Assessing Pathologic Axillary Lymph Node Status in Clinical Stage I-III Breast Cancer Patients: A Systematic Review.

To investigate associations between 18F-FDG-PET/CT semiquantitative and radiomic features with pathologic axillary lymph node (ALN) status in stages I-III breast cancer patients. A search was conducted across MEDLINE, EMBASE, and CENTRAL databases. Quality assessment was performed with QUADAS-2 and the radiomics quality score (RQS). Descriptive statistical analysis was performed. Most studies were retrospective cohort studies (27/28) and reported only on semiquantitative features (26/28). Most studies were at high risk of bias in patient selection (22/28) and feature extraction (26/28). Semiquantitative features included maximum standardized uptake value (SUVmax), metabolic tumour volume (MTV), and total lesion glycolysis (TLG). Although associations between tumour semiquantitative features and ALN status were reported, the mean/median reported values of tumour SUVmax (3.2-8.6 vs. 2.4-9.4), MTV (2.7-19.2 vs. 1.9-10.5), and TLG (10.6-59.3 vs. 5.6-29.6) in ALN+ vs. ALN- patients were inconsistent between studies. Fourteen studies reported a significantly higher ALN SUVmax in ALN+ patients. Two studies developed models using tumour radiomic features with high accuracy for predicting ALN metastases (81.2% and 80%) but scored low on the RQS. Feature-based analysis of PET/CT demonstrates potential for predicting pathologic ALN status in breast cancer patients. However, establishing a clinically meaningful relationship requires higher quality evidence.